Cite
Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo- controlled, 12-week study in early postmenopausal women
MLA
W. M. van Baal, et al. “Oral Oestradiol/Trimegestone Replacement Reduces Procarboxypeptidase U (TAFI): A Randomized, Placebo- Controlled, 12-Week Study in Early Postmenopausal Women.” Journal of Internal Medicine, vol. 251, no. 3, Mar. 2002. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....657454dd25004b888286cacdb295499d&authtype=sso&custid=ns315887.
APA
W. M. van Baal, M.J. van der Mooren, Judith Leurs, Dirk Hendriks, Marinka S. Post, Peter Kenemans, Jef J. Emeis, & Coen D.A. Stehouwer. (2002). Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo- controlled, 12-week study in early postmenopausal women. Journal of Internal Medicine, 251(3).
Chicago
W. M. van Baal, M.J. van der Mooren, Judith Leurs, Dirk Hendriks, Marinka S. Post, Peter Kenemans, Jef J. Emeis, and Coen D.A. Stehouwer. 2002. “Oral Oestradiol/Trimegestone Replacement Reduces Procarboxypeptidase U (TAFI): A Randomized, Placebo- Controlled, 12-Week Study in Early Postmenopausal Women.” Journal of Internal Medicine 251 (3). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....657454dd25004b888286cacdb295499d&authtype=sso&custid=ns315887.